Leland Stanford Junior University

Stanley Watson

Huda Akil

Richard M Myers

Edward G Jones

Cortney Turner

Jun Li

Prabhakara V Choudary

Hiroaki Tomita

Simon J Evans

Marquis P Vawter

Juan F Lopez

Robert C Thompson

Alan F Schatzberg

William E Bunney

Richard A Stein

Margherita Molnar

Mary Atz

William E Bunney, Jr

William E Bunny

William Byerley

Kathleen Casey

Brandi Rollins

David M Lyons

The methods of the present invention are useful for determining whether an individual has or is at risk of developing an affective disorder by detecting the expression level of connective tissue growth factor (CTGF) in a biological sample. The methods of the present invention are also useful for identifying compounds that modulate (e.g., decrease) the expression level or activity of CTGF. The present invention further provides therapeutic methods that target CTGF for the treatment of an affective disorder.

Method for decreasing depression-like behavior with connective tissue growth factor (CTGF) inhibitor

The present invention provides methods for diagnosing mental disorders. The invention also provides methods of identifying modulators of mental disorders as well as methods of using these modulators to treat patients suffering from mental disorders.

Administration of FGF9 for treatment and prevention of major depression

Administration of FGF9 for treatment of anxiety

The present application relates to the treatment and diagnosis of mood disorders, including bipolar disorder, major depression disorder and schizophrenia. The invention provides novel diagnostic markers and assays, as well as research tools for the development and discovery of agents and compounds which are useful for treating patients who suffer from mental illness.

Methods for treating depression using NCAM peptide mimetics

Administration of FGF2 for treamtent of anxiety

The present invention provides methods for diagnosing mental disorders (e.g., psychotic disorders such as schizophrenia and mood disorders such as major depression disorder and bipolar disorder). The invention also provides methods of identifying modulators of such mental disorders as well as methods of using these modulators to treat patients suffering from such mental disorders.

Compositions and methods for diagnosing and treating neuropsychiatric disorders

The present invention provides methods for diagnosing mental disorders such as mood disorders, including bipolar disorder I and II and major depression. The invention also provides methods of identifying modulators of such mental disorders as well as methods of using these modulators to treat patients suffering from such mental disorders.

Compositions and methods for diagnosing and treating mood disorders

Growing community of inventors

Ann Arbor, MI, United States of America

Stanley Watson